The drug is still being evaluated in combination with CDK 4/6 inhibitors in the double-blind randomized persevERA trial in patients with ER+/HER2- locally advanced or metastatic breast cancer (6, 7), The LidERA Phase III multicentric trial, involving 4200 patients with early ER+/HER2- breast cancer, aims to assess the efficacy and safety of adjuvant giredestrant compared to physician’s choice of adjuvant endocrine monotherapy as definitive treatment, providing crucial insights into the optimal therapeutic approach for this patient population (46). The gene discussed is ERBB2; the disease is breast carcinoma.